COST PER RESPONDER ANALYSIS OF GUSELKUMAB VERSUS ETANERCEPT USING EFFICACY RESULTS FROM PIVOTAL CLINICAL TRIALS IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

被引：0
|
作者：
Teeple, A. [1 ]
Muser, E. [1 ]
机构：
[1] Janssen Sci Affairs LLC, Horsham, PA USA
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.1635
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSS14
引用
收藏
页码：S241 / S241
页数：1
相关论文
共 50 条
  • [21] Efficacy of switching from ustekinumab to guselkumab in patients with moderate-to-severe plaque psoriasis: Results from the NAVIGATE study
    Langley, Richard G.
    Tsai, Tsen-Fang
    Flavin, Susan
    Song, Michael
    Randazzo, Bruce
    Wasfi, Yasmine
    Li, Shu
    Puig, Luis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB120 - AB120
  • [22] ABT-874 versus etanercept and placebo in patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results
    Strober, Bruce
    Crowley, Jeffrey
    Valdes, Joaquin
    Gu, Yihua
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB155 - AB155
  • [23] ABT-874 versus etanercept and placebo in patients with moderate to severe chronic plaque psoriasis: efficacy and safety results
    Strober, B.
    Crowley, J.
    Yamauchi, P.
    Yoo, S.
    Gu, Y.
    Valdes, J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2010, 24 : 10 - 11
  • [24] Efficacy and safety results of ABT-874 versus etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
    Gottlieb, Alice
    Leonardi, Craig
    Valdes, Joaquin
    Gu, Yihua
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB159 - AB159
  • [25] COST PER RESPONDER ANALYSIS OF BRODALUMAB COMPARED WITH USTEKINUMAB IN THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN CANADA
    Schembri, J.
    Barbeau, M.
    Gaudet, V
    VALUE IN HEALTH, 2018, 21 : S425 - S425
  • [26] ANALYSIS OF THE COST PER RESPONDER OF BIOLOGICAL TREATMENTS FOR MODERATE TO SEVERE PSORIASIS IN ARGENTINA
    Kanevsky, D.
    Rodriguez, M. F.
    Suarez Ordonez, S.
    Elgart, J.
    Mazzuoccolo, L. D.
    VALUE IN HEALTH, 2020, 23 : S607 - S607
  • [27] Cost effectiveness - Analysis of Therapy with Ustekinumab versus Etanercept in Patients with moderate to severe Plaque Psoriasis Based on the ACCEPT Study
    Augustin, M.
    Feldman, S.
    Wolbring, F.
    Szapary, P.
    Schenkel, B.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2011, 9 : 191 - 191
  • [28] Adding methotrexate to etanercept versus etanercept monotherapy in adults with moderate to severe plaque psoriasis: Efficacy and safety
    Gottlieb, Alice B.
    Strober, Bruce E.
    Kricorian, Gregory
    Langley, Richard G.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB184 - AB184
  • [29] Pharmacokinetics, Immunogenicity, and Efficacy of Etanercept in Pediatric Patients With Moderate to Severe Plaque Psoriasis
    Langley, Richard G.
    Kasichayanula, Sree
    Trivedi, Mona
    Aras, Girish A.
    Kaliyaperumal, Arunan
    Yuraszeck, Theresa
    Gibbs, John
    Gibbs, Megan
    Kricorian, Greg
    Paller, Amy S.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (03): : 340 - 346
  • [30] Cost per response for guselkumab versus adalimumab in the United States using data from a head-to-head trial in moderate-to-severe plaque psoriasis
    Teeple, Amanda
    Muser, Erik
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (12) : 1268 - 1273
12345